Overview of Dr. Abdelrahim
Dr. Maen Abdelrahim is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Clear Lake Hospital. He received his medical degree from Texas A&M; Health Science Center College of Medicine and has been in practice 14 years. He is one of 93 doctors at Houston Methodist Hospital and one of 38 doctors at Houston Methodist Clear Lake Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Texas A&M; Health Science Center College of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2014 - 2027
NC State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Start of enrollment: 2021 Feb 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation.Ashton A Connor, Mahinur Mattohti, Sudha Kodali, Maen Abdelrahim, Ahmed Elaileh
JCO Precision Oncology. 2026-03-01 - Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi
Translational Gastroenterology and Hepatology. 2026-01-01 - 1 citationsAtezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience.Abdullah Esmail, Yazan Hamadneh, Bayan Khasawneh, Maryam Al-Rawi, Ebtesam Al-Najjar
Biomedicines. 2025-11-21
Press Mentions
Surgical Options for Cholangiocarcinoma Enhance SurvivalJuly 19th, 2024- Study Finds Daily Aspirin Use Improves Colorectal Cancer OutcomesJuly 19th, 2024
New Recommendation to Start Colorectal Cancer Screenings at Age 45: What to KnowFebruary 4th, 2020
Grant Support
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
